ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 1749 • ACR Convergence 2020

    Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis

    Daniel Aletaha1, Rene Westhovens2, Cecile Gaujoux-Viala3, Giovanni Adami4, Alan Matsumoto5, Paul Bird6, Osvaldo Daniel Messina7, Maya Buch8, Beatrix Bartok9, Zhaoyu Yin9, Ying Guo10, Thijs Hendrikx11 and Gerd Burmester12, 1Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, 2University Hospitals Leuven, Belgium, Leuven, Belgium, 3Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, 4University of Verona, Verona, Italy, 5Arthritis and Rheumatism Assoc, Wheaton, MD, 6University New South Wales, Sydney, Australia, 7IRO Medical Ctr & Cosme Argerich Hospital, Buenos Aires, Argentina, 8Centre of Musculoskeletal Research, School of Biological Sciences, University of Manchester, Manchester, United Kingdom, 9Gilead Sciences, Inc., Foster City, CA, 10Gilead Sciences, Inc., Foster City, 11Galapagos BV, Leiden, Netherlands, 12Charité University Hospital Berlin, Berlin, Germany

    Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…
  • Abstract Number: 1750 • ACR Convergence 2020

    Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial

    Juergen Rech1, Hannah Schenker2, Koray Tascilar1, Melanie Hagen2, Larissa Valor Mendez2, Verena Schoenau3, Marina Sergeeva4, Jutta Prade4, Mageshvar Sulvakumar5, Laura Konert6, Arnd Kleyer1, David Simon1, Sandra Strobelt4, Frank Behrens7, Christoph Baerwald8, Stephanie Finzel9, Reinhard Voll10, Axel Hueber11, Eugen Feist12, Julie Roesch13, José A. P. da Silva14, Arnd Doerfler13, Nemanja Damjanov15, Andreas Hess16 and Georg Schett17, 1Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, 4Institute for Experimental Pharmacology, Erlangen, Germany, 5Insitute for Experimental Pharmacology, FAU Erlangen-Nuremberg, Erlangen, Germany, 6Institute for Experimental Pharmacology, FAU Erlangen-Nürnberg, Erlangen, 7CIRI/Rheumatology & Fraunhofer TMP, Goethe University, Frankfurt, Germany, 8Uniklinik Leipzig, Medizinische Klinik III - Bereich Rheumatologie, Leipzig, Germany, 9Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freiburg, Germany, 10Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Freibrug, 11Section Rheumatology, Sozialstiftung Bamberg, Bamberg, Germany, 12Department of Rheumatology, Helios Vogelsang-Gommern, Vogelsang-Gommern, Germany, 13Abteilung für Neuroradiologie, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany, Erlangen, Germany, 149.Centro Hospitalar e Universitário Coimbra (Rheumatology Department), Coimbra, Portugal, Coimbra, Portugal, 15Belgrade University School of Medicine, Belgrade, Serbia, 16Institute for Experimental Pharmacology, Erlangen, 17Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany

    Background/Purpose: Biologicals - bring a hope of recovery or amelioration to people suffering from RA, but only half of the patients respond to such treatment.…
  • Abstract Number: 1751 • ACR Convergence 2020

    Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center

    Elston He1, Eli Cornblath2, Pratyusha Yalamanchi3, Alexis Ogdie2, Joshua Baker2 and Michael George2, 1Synovium, Inc., Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
  • Abstract Number: 1752 • ACR Convergence 2020

    Prediction of Responder and Non-responder to JAK Inhibitors in Patients with Rheumatoid Arthritis: A Pilot Study with Integrative Cluster Analysis

    Masanari Sugawara1, Yuichiro Fujieda2, Atsushi Noguchi3, Shun Tanimura4, Yuka Shimizu5, Ikuma Nakagawa6, Hiroki Takahashi7, Michihito Kono8, Masaru Kato2, Kenji Oku2, Olga Amengual2 and Tatsuya Atsumi9, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo city, Hokkaido, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 3Department of Internal Medicine and General Medicine, Japanese Red Cross Kitami Hospital, Sapporo, Japan, 4Department of Internal Medicine, Tomakomai City Hospital, Tomakomai, Hokkaido, Japan, 53rd Department of Internal medicine, Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Sapporo, Japan, 6Department of Internal Medicine, Takikawa Municipal Hospital, Sapporo, Japan, 7Department of Rheumatology and Clinical Immunology, Sapporo Medical University School of Medicine, Sapporo, Japan, 8Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University, Sapporo, Japan, 9Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose: [Background]Oral Janus kinase inhibitors (JAKi) show dramatical efficacy to reduce the disease activity in patients with rheumatoid arthritis (RA). However, there remain some patients who…
  • Abstract Number: 1753 • ACR Convergence 2020

    Substantial Work Limitations in Patients with Rheumatoid Arthritis Despite Optimal Treat-to-Target (T2T) Drug Therapy Intervention

    Sara Eileen Meyer1, Julianna Rachel Hoeper2, Kirsten Hoeper1, Torsten Witte3 and Dirk Meyer-Olson4, 1Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hanover, Germany, 2Center for Health Economics Research Hannover, Leibniz Universität Hannover, Hannover, Hanover, Germany, 3Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., Hannover, Germany, 4Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie und Regionales Kooperatives Rheumazentrum Niedersachsen e.V., m&i Fachklinik Bad Pyrmont und Medizinisches Forschungszentrum Weserbergland, Hanover, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is associated with restrictions on occupational participation caused by periods of sick leave (absenteeism), reduced productivity at work due to disease…
  • Abstract Number: 1754 • ACR Convergence 2020

    The Point of No Return? Functional Disability in Patients with Rheumatoid Arthritis versus the General Population: Results from a Population-based Cohort Study

    Elena Myasoedova1, John Davis1, Vanessa Kronzer1, Rachel Giblon1, Elizabeth Atkinson1 and Cynthia Crowson2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Despite the advances in treatment of rheumatoid arthritis (RA), many patients do not achieve remission or full physical functioning. We have previously shown that…
  • Abstract Number: 1755 • ACR Convergence 2020

    Body Mass Index Trajectory and Variability in Rheumatoid Arthritis

    Gregory Challener1, Elena Myasoedova1, Cynthia Crowson2, Rachel Giblon1 and John Davis1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

    Background/Purpose: Past studies have examined associations between BMI and disease activity [1, 2, 3], but few studies have characterized BMI trajectory over the disease course…
  • Abstract Number: 1756 • ACR Convergence 2020

    Comparable Long-Term Outcomes Among DAS28-ESR-based Remission Criteria and ACR/EULAR Definitions in Patients with Established Rheumatoid Arthritis

    Felipe Julio Ramirez Garcia1, Jose Inciarte-Mundo2, Andrea Cuervo3, Raquel Celis4, Virginia Ruiz-Esquide4, Raul Castellanos-Moreira5, Andres Ponce4, Jose Gómez-Puerta6, Raimon Sanmartí6 and Juan Cañete7, 1Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, 2Hospital Universitari Clínic de Barcelona, Barcelona, 3Hospital Clínic, Barcelona, Spain, 4Hospital Clinic, Barcelona, Spain, 5Hospital Clinic of Barcelona, Barcelona, Spain, 6Hospital Universitari Clínic de Barcelona, Barcelona, Catalonia, Spain, 7Arthritis Unit, Rheumatology Dpt, Hospital Clinic, Barcelona, Spain and IDIBAPS, Barcelona, Spain

    Background/Purpose: To compare long-term clinical and radiographic outcomes among five sets of remission criteria [four clinical and one Ultrasound (US)-based] in a cohort of RA…
  • Abstract Number: 1757 • ACR Convergence 2020

    High-Intensity Interval Training Increases Rheumatoid Arthritis Cardiorespiratory Fitness in Association with Improvements in CD4+ T Cell and Skeletal Muscle Mitochondrial Metabolism

    Brian Andonian1, David Bartlett1, Alec Koss1, Deborah Muoio1, Timothy Koves1, Eugene St Clair1, Elizabeth Hauser1, William Kraus1 and Kim Huffman1, 1Duke University, Durham, NC

    Background/Purpose: Persons with rheumatoid arthritis (RA) have poor cardiorespiratory fitness and are at increased risk for cardiometabolic co-morbidities. Endurance exercise training improves cardiorespiratory fitness in…
  • Abstract Number: 1758 • ACR Convergence 2020

    Prevalence and Incidence of Infection and Venous Thromboembolism in Rheumatoid Arthritis Patients Newly Initiating Various DMARD Classes: Real-World Analysis of 2012–2016 US Medicare Data

    Robin Dore1, Jenya Antonova2, Lawrence Chang2, Suying Li3, Haifeng Guo3, Yuanyuan Ji3 and Mark Genovese4, 1Private practice, Tustin, CA, 2Gilead Sciences, Foster City, CA, 3Chronic Disease Research Group, Minneapolis, MN, 4Stanford University Medical Center, Palo Alto, CA

    Background/Purpose: RA patients have an increased risk of infection1 and venous thromboembolism (VTE)2. Although rates of serious infection and VTE have been reported for Medicare…
  • Abstract Number: 1759 • ACR Convergence 2020

    Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study

    Melissa Castillo-Bustamante1, Marc Polanik1, Dhrumi Gandhi1, Elliott Kozin1 and Aaron Remenschneider1, 1Massachusetts Eye and Ear Infirmary/Harvard University, Boston, MA

    Background/Purpose: Inflammation of synovial joints in small and large extremities is commonly seen in Rheumatoid arthritis (RA). To date little is known about how this disease…
  • Abstract Number: 1760 • ACR Convergence 2020

    The Association Between the Risk of Venous Thromboembolism and Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Observational Study

    Masaru Yoshimura1, Yuichiro Fujieda2, Michihito Kono2, Masaru Kato2, Kenji Oku2, Olga Amengual2 and Tatsuya Atsumi3, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapparo, Hokkaido, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is an immune-mediated synovial disease with chronic inflammation. Systemic inflammation is considered one of risk factors for venous thromboembolism (VTE), which…
  • Abstract Number: 1761 • ACR Convergence 2020

    Rheumatoid Arthritis Inpatient Mortality: An Analysis of the National Inpatient Sample

    Ehizogie Edigin1, Precious Eseaton2 and Augustine Manadan3, 1John H Stroger Jr. Hospital of Cook County, Chicago, IL, 2University of Benin Teaching Hospital, Benin, 3Cook County Hospital/Rush University Medical center, Chicago, IL

    Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease with increased mortality. Little national-level data is available on inpatient mortality in RA patients. In this…
  • Abstract Number: 1762 • ACR Convergence 2020

    Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA

    Alvin Wells1, Kirstin Griffing2, Amanda Quebe2, Luna Sun2, Hong Zhang3 and Paulo Reis2, 1Aurora Rheumatology and Immunotherapy Center, Franklin, 2Eli Lilly and Company, Indianapolis, IN, 3Tech Data Services, King of Prussia, PA

    Background/Purpose: In clinical practice, drug treatment decisions must account for the expected benefit from a drug along with its potential risks. Evaluating the number needed…
  • Abstract Number: 1763 • ACR Convergence 2020

    Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis

    Robert Landewé1, Daniel H Solomon2, Gianluca Bonfanti3, Luigi Manca3, John C Woolcott4, Jasper Deuring5, Stephen Watt6, Pritha Bhadra Brown6, Rebecca Germino6, Birol Emir6 and Roger A Edwards7, 1Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, 2Brigham and Women's Hospital, Boston, MA, 3Fair Dynamics Consulting, SRL, Milan, Italy, 4Pfizer Inc, Collegeville, PA, 5Pfizer Inc, Rotterdam, Netherlands, 6Pfizer Inc, New York, NY, 7Health Services Consulting Corporation, Boxborough, MA

    Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…
  • « Previous Page
  • 1
  • …
  • 951
  • 952
  • 953
  • 954
  • 955
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology